TY - JOUR
KW - Abuse treatment
KW - access to care
KW - buprenorphine
KW - Drug Use
KW - Health Policy
KW - medical treatment
KW - opioid use disorder
KW - patient care
KW - primary care providers
KW - Psychiatrists
KW - Substance use disorder
KW - health conditions
AU - M. Olfson
AU - V. Zhang
AU - M. Schoenbaum
AU - M. King
A1 - 
AB - Substantial increases in opioid-related morbidity and mortality have motivated the implementation of federal policies to expand the buprenorphine prescribing capacity of primary care providers and other clinicians. Using a national prescription database that covered 72-92 percent of the US population during 2010-18, we analyzed trends in buprenorphine treatment by prescriber specialty. Buprenorphine treatment rates by primary care providers increased from 12.9 people per 10,000 population in 2010 to 27.4 in 2018. The numbers for psychiatrists and addiction medicine specialists increased from 8.7 to 12.0 per 10,000 and those for other prescribers from 5.8 to 16.3 per 10,000. However, treatment of people ages 15-24 by primary care providers and by psychiatrists and addiction medicine specialists declined significantly. Across all patient age and provider groups, most patients were not retained on buprenorphine for the benchmark period of at least 180 days. Despite a recent national increase in buprenorphine treatment fueled primarily by nonspecialists, challenges persist with buprenorphine access-especially for younger people-and with retaining patients in long-term treatment.
AD - Mark Olfson (mo49@cumc.columbia.edu) is the Elizabeth K. Dollard Professor of Psychiatry, Medicine, and Law in the Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University; a professor of epidemiology in the Mailman School of Public Health, Columbia University; and a research psychiatrist at the New York State Psychiatric Institute, all in New York City.; Victoria Zhang is a postdoctoral research associate at the School of Management, Yale University, in New Haven, Connecticut.; Michael Schoenbaum is a senior adviser for mental health services at the National Institute of Mental Health, in Bethesda, Maryland.; Marissa King is a professor of management and sociology at the School of Management and Department of Sociology, Yale University.
BT - Health affairs (Project Hope)
C5 - Education & Workforce; Healthcare Disparities; Healthcare Policy; Opioids & Substance Use
CP - 6
CY - United States
DO - 10.1377/hlthaff.2019.01622
IS - 6
JF - Health affairs (Project Hope)
LA - eng
M1 - Journal Article
N2 - Substantial increases in opioid-related morbidity and mortality have motivated the implementation of federal policies to expand the buprenorphine prescribing capacity of primary care providers and other clinicians. Using a national prescription database that covered 72-92 percent of the US population during 2010-18, we analyzed trends in buprenorphine treatment by prescriber specialty. Buprenorphine treatment rates by primary care providers increased from 12.9 people per 10,000 population in 2010 to 27.4 in 2018. The numbers for psychiatrists and addiction medicine specialists increased from 8.7 to 12.0 per 10,000 and those for other prescribers from 5.8 to 16.3 per 10,000. However, treatment of people ages 15-24 by primary care providers and by psychiatrists and addiction medicine specialists declined significantly. Across all patient age and provider groups, most patients were not retained on buprenorphine for the benchmark period of at least 180 days. Despite a recent national increase in buprenorphine treatment fueled primarily by nonspecialists, challenges persist with buprenorphine access-especially for younger people-and with retaining patients in long-term treatment.
PP - United States
PY - 2020
SN - 1544-5208; 0278-2715
SP - 984
EP - 992
EP - 
T1 - Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others
T2 - Health affairs (Project Hope)
TI - Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others
U1 - Education & Workforce; Healthcare Disparities; Healthcare Policy; Opioids & Substance Use
U2 - 32479224
U3 - 10.1377/hlthaff.2019.01622
VL - 39
VO - 1544-5208; 0278-2715
Y1 - 2020
Y2 - Jun
ER -